arrow
S

Stefan Siebert

university of glasgow
H指数:46
被引数:8,017

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease

PEPITEM 在免疫介导性炎性关节炎期间调控滑膜微环境以限制疾病

2026-04-010
OAAI
Differentiating the COVID-19 Infection and Vaccine Experiences of Patients With Systemic, Single Organ, and Overlap Immune-Mediated Inflammatory Disease: Protocol for a Secondary Analysis for Enhancing COVID-19 Vaccine Pharmacovigilance

区分系统性、单器官和重叠自身免疫介导性炎症疾病患者的COVID-19感染和疫苗接种经历:用于增强COVID-19疫苗药物警戒的二次分析方案

2026-01-010
PRE
How do musculoskeletal disorders impact on quality of life in Tanzania? Results from a community-based survey

肌肉骨骼疾病如何影响坦桑尼亚的生活质量?社区调查结果

2025-12-010
OA
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles

DESTINIES研究:一项在线德尔菲研究,旨在就赋予免疫抑制的医疗条件和程序及其各自的COVID-19风险特征建立国际共识

2025-05-010
OAAI
Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis outcomes: 6-month interim results of the PsABIOnd observational cohort study

Guselkumab和IL-17抑制剂在银屑病关节炎结局方面显示出可比的治疗持续性和有效性:PsABIOnd观察性队列研究的6个月中期结果

2025-04-280
PRE
Factors associated with biologics treatment response at 1 year amongst patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA)

与银屑病关节炎患者生物制剂治疗1年应答相关的因素——英国风湿病学会银屑病关节炎登记研究(BSR-PsA)的结果

2025-04-280
PRE
Guselkumab and IL-17 inhibitors improve patient-perceived impact of psoriatic arthritis similarly: 6-month interim results of the PsABIOnd observational cohort study

Guselkumab和IL-17抑制剂对银屑病关节炎患者感知影响的改善效果相似:PsABIOnd观察性队列研究的6个月中期结果

2025-04-280
PRE
Patient-reported outcomes as early warning signals of flare following drug cessation in rheumatoid arthritis

患者报告结局作为药物停用后类风湿关节炎复发的早期预警信号

2025-04-280
PRE
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

执行摘要:2025年英国风湿病学会关于使用生物制剂和靶向合成DMARDs治疗轴向脊柱关节炎的指南

2025-04-090
PRE
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

2025年英国风湿病学会关于使用生物制剂和靶向合成DMARDs治疗轴向脊柱关节炎的指南

2025-04-090
PRE
Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis

患者报告结局作为药物停用后类风湿关节炎复发的早期预警信号

2025-04-010
OA
BASELINE CHARACTERISTICS OF REAL-WORLD PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB OR IL-17 INHIBITORS: RESULTS FROM THE ONGOING MULTINATIONAL PSABIOND STUDY

真实世界接受GUSelkumab或IL-17抑制剂治疗的银屑病关节炎患者的基线特征:来自正在进行的多国PSABIOND研究的结果

2024-06-010
PRE
PSORIATIC ARTHRITIS PATIENT PROFILES ARE DIFFERENT BETWEEN RANDOMISED CONTROLLED TRIALS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND A REAL-WORLD STUDY OVERTHE SAME TIMEFRAME (PSABIO)- A LITERATURE REVIEW WITH META-ANALYSIS

银屑病关节炎患者特征在生物类改善病情抗风湿药物随机对照试验与同期真实世界研究(PSABIO)中存在差异——一项文献综述与荟萃分析

2024-06-010
PRE